Plazomicin

Plazomicin
Clinical data
Pronunciationpla" zoe mye' sin
Trade namesZemdri
Other namesACHN-490,
6'-(Hydroxylethyl)-1-(HABA)-sisomicin
AHFS/Drugs.comMonograph
MedlinePlusa618037
License data
Routes of
administration		Intravenous
Drug classAminoglycoside
ATC code
Legal status
Legal status
Identifiers
  • (2S)-4-Amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[[(2S,3R)-3-amino-6-[(2-hydroxyethylamino)methyl]-3,4-dihydro-2H-pyran-2-yl]oxy]-2-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC25H48N6O10
Molar mass592.691 g·mol−1
3D model (JSmol)
  • CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(=CC[C@H]3N)CNCCO)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CCN)OC[C@]1(C)O
  • InChI=1S/C25H48N6O10/c1-25(37)11-38-24(18(35)21(25)29-2)41-20-15(31-22(36)16(33)5-6-26)9-14(28)19(17(20)34)40-23-13(27)4-3-12(39-23)10-30-7-8-32/h3,13-21,23-24,29-30,32-35,37H,4-11,26-28H2,1-2H3,(H,31,36)/t13-,14+,15-,16+,17+,18-,19-,20+,21-,23-,24-,25+/m1/s1
  • Key:IYDYFVUFSPQPPV-PEXOCOHZSA-N

Plazomicin, sold under the brand name Zemdri, is an aminoglycoside antibiotic used to treat complicated urinary tract infections.[2] As of 2019 it is recommended only for those in whom alternatives are not an option.[2] It is given by injection into a vein.[2]

Common side effects include kidney problems, diarrhea, nausea, and blood pressure changes.[2] Other severe side effects include hearing loss, Clostridioides difficile-associated diarrhea, anaphylaxis, and muscle weakness.[2] Use during pregnancy may harm the baby.[2] Plazomicin works by decreasing the ability of bacteria to make protein.[2]

Plazomicin was approved for medical use in the United States in 2018.[3][4] It is on the World Health Organization's List of Essential Medicines.[5]

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  2. ^ a b c d e f g "Plazomicin Sulfate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 August 2020. Retrieved 10 October 2019.
  3. ^ Cite error: The named reference FDA Zemdri 210303 was invoked but never defined (see the help page).
  4. ^ "Drug Approval Package: Zemdri (plazomicin)". U.S. Food and Drug Administration. 5 July 2018. Archived from the original on 28 November 2020. Retrieved 25 December 2019.
  5. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.